Forecast

There is no analyst data available for this company.

News Go to news feed

MustGrow advances commercialization with TerraSante registrations, Bayer testing agreement and C$3.74m financing

MustGrow is expanding commercial rollout of its mustard-derived product TerraSante with new U.S. registrations including Texas, broadening its market access. The company has an exclusive agreement with Bayer for testing and potential rights to several applications across EMEA and APAC, with Bayer funding development and regulatory work. MustGrow completed a C$3.74 million private placement to fund inventory and working capital and received a BUY initiation from GBC with upside revenue forecasts, while commercial adoption and regulatory progress remain key execution risks. » More on finance.yahoo.com
MustGrow Biologics posts surge in 2025 revenue as TerraSante US sales accelerate

MustGrow Biologics reported revenue of $8.3m for 2025, up from $0.4m in 2024, driven by strong US sales of its TerraSante biofertility product. US TerraSante sales rose to $0.6m, a 377% increase, while gross margin was 20%. Operating expenses increased to $7.7m, widening the net loss to $7.3m as the company scaled commercial activity and third-party manufacturing. Management expects continued TerraSante sales growth and margin improvement in 2026 as production shifts to continuous contract manufacturing and US tariffs become more favorable. » More on finance.yahoo.com
MustGrow Biologics boosts gross margin in Q3 despite net loss

MustGrow Biologics reported an improved gross margin of 22% for Q3 2025 alongside a net loss of $2.4 million. Revenue of $180,560 fell well short of expectations of $5.2 million, while EPS of -0.04 matched forecasts. The stock rose 6.78% after the results. The company is targeting cash-flow break-even in 2026 and plans expansion in Brazil, Mexico and the Netherlands, but sees risks from inventory shortages, tariffs and regulatory hurdles. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2010, MustGrow Biologics has already paid €0.78 in dividends. The last payout was in August 2010.

Financials

In the last quarter, MustGrow Biologics had revenue of €887.33K and net profit of €175.65K

(EUR)	Jun 2026	YoY
Revenue	887.33K	50.06%
Gross profit	840.14K	126.55%
Net profit	175.65K	125.87%
EBITDA	265.21K	141.57%

Fundamentals

Metric	Value
Market capitalization	€18.3M
Number of shares	62.96M
52-week high/low	€0.58 - €0.19
Dividends	No
Beta	0.33
P/E ratio	-4.90
PEG ratio	-0.71
P/B ratio	6.01
P/S ratio	8.49

Company profile

MustGrow Biologics Corp. ist ein landwirtschaftliches Biotech-Unternehmen, das sich auf die Entwicklung und Vermarktung von natürlichen Biopestiziden, Biofumigants und Bioherbiziden aus Senfsamen konzentriert. Das Unternehmen bietet Biofumigation vor der Aussaat an, eine Technologie zur Behandlung von Krankheiten und Schädlingen, die durch den Boden übertragen werden, für verschiedene Kulturpflanzen, einschließlich Obst, Gemüse und andere Kulturen. Das Unternehmen entwickelt außerdem Bioherbizide zur Behandlung unerwünschten Pflanzenwachstums für den Einsatz in der ökologischen Landwirtschaft, im Haus- und Gartenbereich sowie in der Landwirtschaft. Darüber hinaus konzentriert sich das Unternehmen auf die Bereitstellung von CannaPM, einem Wirkstoff zur Behandlung von Pilzkrankheiten im Boden und von Blattkrankheiten. Das Unternehmen war früher als Duport Capital Ltd. bekannt und änderte im März 2018 seinen Namen in MustGrow Biologics Corp. MustGrow Biologics Corp. wurde im Jahr 2014 gegründet und hat seinen Hauptsitz in Saskatoon, Kanada.

Name	MustGrow Biologics
CEO	Corey J. Giasson
Headquarters	Saskatoon, sk Canada
Website	mustgrow.ca
Sector	Health Care
Industry	Biotechnology
IPO	11/21/2019
Employees	10